


The circularized Solnatide peptides are being developed by APEPTICO for treatment of life-threatening conditions & unmet clinical diseases:

- Pulmonary Permeability Oedema / ARDS
- Acute Respiratory Failure / COVID-19
- High Altitude Pulmonary Oedema
- Ischemia Reperfusion Injury
- Primary Graft Dysfunction
- Pseudohypoaldosteronism Type 1B

Solnatide




Acute Respiratory Failure & Pulmonary Permeability Oedema account for 10% of all ICU admissions, representing 5 million patients annually.

Solnatide (INN) is the first and exclusivity compound that accelerated Alveolar Liquid Clearance in two RCT and that restored physiological lung function in mechanically ventilated patients with life-threatening Pulmonary Permeability Oedema, and in patients with Primary Graft Dysfunction following Lung Transplantation. Following application of Solnatide aerosol, the peptide enhances ENaC expression at gene level and it activates the ENaC (epithelial sodium ion channel) to brings about pulmonary oedema clearance. Solnatide also exerts an inhibitory effect on the pro-inflammatory pathways by reducing the synthesis of cytokines. Solnatide increased the expression of the tight junction protein occludin, thereby improving the stability of the alveolar capillary barriers.

- Solnatide is only active in the airspace and does not penetrate into circulation.
- Solnatide protects the endothelial-epithelial barrier function and prevents alveolar micro-capillary leakage.
- Solnatide counteracts microbial toxins, influenza virus infection and reactive oxygen species (ROS).
- Solnatide inhibits the pro-inflammatory pathway and increases the expression of the tight junction protein occludin.
- ✓ Solnatide was safe and well tolerated in a Phase I clinical study.
- ✓ Solnatide demonstrated clinical efficacy in a Phase II clinical study in mechanically ventilated patients suffering from life-threatening Pulmonary Permeability Oedema & ARDS.
- ✓ Solnatide demonstrated safety and clinical benefit during treatment of patients with moderate-severe COVID-19.
- ✓ Solnatide demonstrated clinical efficacy in a Phase II clinical study in patients with Primary Graft Dysfunction (PGD) following Lung Transplantation.
- ✓ Solnatide has been granted Compassionate Use for the treatment of patients with moderate to severe COVID-19.

Currently, Solnatide represents a Total rNPV of \$ 975 Million and a Peak Revenues of \$ 1,240 Million in USA, \$ 495 Million in EU and \$ 137 Million in Japan.




Solnatide is ready for the Phase III clinical trials for treatment of Pulmonary Permeability Oedema / ARDS / COVID-19 and Treatment of PGD following LTX.

Description of Target Indications for Solnatide


Page: 1

<p>Solnatide</p>	<p><u>Solnatide (AP301), is a synthetic, cyclic peptide that</u></p> <ul style="list-style-type: none"> ➤ activates Alveolar Liquid Clearance in the airspace following inhalation of Solnatide aerosol into the lung ➤ activates the amiloride-sensitive epithelial sodium channel complex (ENaC) in human epithelial and endothelial lung cells ➤ protects the endothelial / epithelial barrier function from virulence factors of common lung pathogenic bacteria and viruses by blunting Protein Kinase C-α activation and MLC phosphorylation and by decreasing intracellular levels of reactive oxygen species (ROS) ➤ exerts an inhibitory effect on the pro-inflammatory pathway by reducing the synthesis of cytokines. Solnatide increases the expression of the tight junction protein occludin, thereby improving the stability of the capillary barriers.
<p>Indications</p>	<p><u>Treatment of Pulmonary Permeability Oedema in ARDS & COVID-19</u> Pulmonary permeability oedema is a life-threatening condition in patients with a variety of underlying clinical diseases. Lung tissue is injured directly (pneumonia) or indirectly (sepsis, burs, inflammation) and blood fluid penetrates into the alveoli thus preventing normal gas exchange. Acute Respiratory Failure & Pulmonary Permeability Oedema account for 10% of all ICU admissions, representing 5 million patients annually. <i>Currently, no specific therapy is available.</i></p> <p><u>Treatment of Primary Graft Dysfunction (PGD) following Lung Transplant</u> Following lung transplant procedure, ischemia reperfusion injury triggers formation of a life-threatening pulmonary oedema. Lung oedema causes lung dysfunction and acute graft rejection immediately after lung transplantation. <i>Currently, no specific therapy is available.</i></p> <p><u>Treatment of High Altitude Pulmonary Oedema (HAPE)</u> HAPE is a life-threatening complication of rapid ascents to altitudes higher than 3,000 m. Climatic and environmental changes lead to exaggerated pulmonary hypertension leading to vascular leakage through over-perfusion, stress failure, or both. <i>Currently, no specific therapy is available.</i></p> <p><u>Treatment of Pseudohypoaldosteronism 1B (PHA)</u> PHA is characterised by salt wasting from the kidney, colon, and sweat and salivary glands leading to high concentrations of sodium in sweat, stool, and saliva. The disorder involves multiple organ systems and is especially threatening in the neonatal period. <i>Currently, no specific therapy is available.</i></p>
<p>Status</p>	<ul style="list-style-type: none"> • Phase I and two Phase II trials are completed. • Efficacy, safety and tolerability established. • APEPTICO prepares to initiate Phase III pivotal clinical trials.

APEPTICO is a clinical stage biotechnology company with operations in Vienna/Austria. We focus on the identification, validation and commercialisation of innovative peptide-based therapeutics for the treatment of chronic and life-threatening diseases.



The company has a core competence in the identification of bio-active peptide structures and converting this knowledge into novel therapeutic approaches for diseases with high medical need.



We collect molecular, structural, biological & medicinal data of well-characterised proteins and biopharmaceuticals in our proprietary data base PEPBASE™.

Our peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. All our products address highly profitable and growing markets.

With the identification of a bio-active moiety we start PEPSCREEN™, our fast-track product development pathway.

